{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T07:52:20Z","timestamp":1723276340426},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,4,21]],"date-time":"2015-04-21T00:00:00Z","timestamp":1429574400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s12282-015-0612-0","type":"journal-article","created":{"date-parts":[[2015,4,20]],"date-time":"2015-04-20T10:54:43Z","timestamp":1429527283000},"page":"617-623","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Fulvestrant 500\u00a0mg in postmenopausal patients with metastatic breast cancer: the initial clinical experience"],"prefix":"10.1007","volume":"23","author":[{"given":"Naoko","family":"Ishida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Araki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiko","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kokoro","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ippei","family":"Fukada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuchika","family":"Hosoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsugu","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuomi","family":"Ichinokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunji","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuji","family":"Iwase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,4,21]]},"reference":[{"key":"612_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-015-0793-8","author":"H Iwase","year":"2015","unstructured":"Iwase H, Yamamoto Y. Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer. Int J Clin Oncol. 2015; doi: 10.1007\/s10147-015-0793-8 .","journal-title":"Int J Clin Oncol"},{"key":"612_CR2","first-page":"3867","volume":"51","author":"AE Wakeling","year":"1991","unstructured":"Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991;51:3867\u201373.","journal-title":"Cancer Res"},{"key":"612_CR3","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/1097-0142(20000815)89:4<817::AID-CNCR14>3.0.CO;2-6","volume":"89","author":"A Howell","year":"2000","unstructured":"Howell A, Osborne CK, Morris C, Wakeling AE. ICI 182,780 (Faslodex): development of a novel, \u201cpure\u201d antiestrogen. Cancer. 2000;89:817\u201325.","journal-title":"Cancer"},{"key":"612_CR4","first-page":"6739","volume":"61","author":"JF Robertson","year":"2001","unstructured":"Robertson JF, Nicholson RI, Bundred NJ, Anderson E, Rayter Z, Dowsett M, et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res. 2001;61:6739\u201346.","journal-title":"Cancer Res"},{"key":"612_CR5","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2002.10.057","volume":"20","author":"A Howell","year":"2002","unstructured":"Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol. 2002;20:3396\u2013403.","journal-title":"J Clin Oncol"},{"key":"612_CR6","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1200\/JCO.2002.10.058","volume":"20","author":"CK Osborne","year":"2002","unstructured":"Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002;20:3386\u201395.","journal-title":"J Clin Oncol"},{"key":"612_CR7","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1200\/JCO.2010.28.8415","volume":"28","author":"A Leo Di","year":"2010","unstructured":"Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250\u00a0mg with fulvestrant 500\u00a0mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;28:4594\u2013600.","journal-title":"J Clin Oncol"},{"key":"612_CR8","first-page":"337","volume":"106","author":"A Leo Di","year":"2014","unstructured":"Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, et al. Final overall survival: fulvestrant 500\u00a0mg vs 250\u00a0mg in the randomized CONFIRM trial. J Natl Cancer Inst. 2014;106:337.","journal-title":"J Natl Cancer Inst"},{"key":"612_CR9","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1093\/annonc\/mdq249","volume":"21","author":"S Ohno","year":"2010","unstructured":"Ohno S, Rai Y, Iwata H, Yamamoto N, Yoshida M, Iwase H, et al. Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1). Ann Oncol. 2010;21:2342\u20137.","journal-title":"Ann Oncol"},{"key":"612_CR10","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s10549-010-1022-9","volume":"123","author":"KI Pritchard","year":"2010","unstructured":"Pritchard KI, Rolski J, Papai Z, Mauriac L, Cardoso F, Chang J, et al. Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2). Breast Cancer Res Treat. 2010;123:453\u201361.","journal-title":"Breast Cancer Res Treat"},{"key":"612_CR11","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1200\/JCO.2000.18.11.2234","volume":"18","author":"PE Lonning","year":"2000","unstructured":"Lonning PE, Bajetta E, Murray R, Tubiana-Hulin M, Eisenberg PD, Mickiewicz E, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol. 2000;18:2234\u201344.","journal-title":"J Clin Oncol"},{"key":"612_CR12","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.breast.2005.08.032","volume":"15","author":"N Steele","year":"2006","unstructured":"Steele N, Zekri J, Coleman R, Leonard R, Dunn K, Bowman A, et al. Exemestane in metastatic breast cancer: effective therapy after third-generation non-steroidal aromatase inhibitor failure. Breast. 2006;15:430\u20136.","journal-title":"Breast."},{"key":"612_CR13","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/S0959-8049(03)00602-6","volume":"39","author":"B Thurlimann","year":"2003","unstructured":"Thurlimann B, Robertson JF, Nabholtz JM, Buzdar A, Bonneterre J. Efficacy of tamoxifen following anastrozole (\u2018Arimidex\u2019) compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur J Cancer. 2003;39:2310\u20137.","journal-title":"Eur J Cancer"},{"key":"612_CR14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/1471-2407-13-239","volume":"13","author":"Y Yamamoto","year":"2013","unstructured":"Yamamoto Y, Ishikawa T, Hozumi Y, Ikeda M, Iwata H, Yamashita H, et al. Randomized controlled trial of toremifene 120\u00a0mg compared with exemestane 25\u00a0mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer. BMC Cancer. 2013;13:239.","journal-title":"BMC Cancer"},{"key":"612_CR15","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2007.13.5822","volume":"26","author":"S Chia","year":"2008","unstructured":"Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008;26:1664\u201370.","journal-title":"J Clin Oncol"},{"key":"612_CR16","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366:520\u20139.","journal-title":"N Engl J Med"},{"key":"612_CR17","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2011.39.0708","volume":"30","author":"T Bachelot","year":"2012","unstructured":"Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol. 2012;30:2718\u201324.","journal-title":"J Clin Oncol"},{"key":"612_CR18","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/ng.2822","volume":"45","author":"W Toy","year":"2013","unstructured":"Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013;45:1439\u201345.","journal-title":"Nat Genet"},{"key":"612_CR19","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/ng.2823","volume":"45","author":"DR Robinson","year":"2013","unstructured":"Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45:1446\u201351.","journal-title":"Nat Genet"},{"key":"612_CR20","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-13-2332","volume":"20","author":"R Jeselsohn","year":"2014","unstructured":"Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, et al. Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res. 2014;20:1757\u201367.","journal-title":"Clin Cancer Res"},{"key":"612_CR21","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s12282-009-0148-2","volume":"17","author":"Y Yamamoto","year":"2010","unstructured":"Yamamoto Y, Masuda N, Ohtake T, Yamashita H, Saji S, Kimijima I, et al. Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor. Breast Cancer. 2010;17:254\u201360.","journal-title":"Breast Cancer."}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-015-0612-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12282-015-0612-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-015-0612-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T16:40:58Z","timestamp":1559580058000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12282-015-0612-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,21]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["612"],"URL":"https:\/\/doi.org\/10.1007\/s12282-015-0612-0","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,21]]}}}